One particularly exciting area where we are placing our Partnering efforts is in Neuroscience. Following the science is taking us into an area of enormous need and opportunity for scientific progress in diseases of the brain and nervous system.
Four efforts also built one of the strongest and most diverse pipelines in the industry with four late stage investigational medicines and 2 potential new molecular entity (NME) approvals in 2020, spanning the spectrum of nervous system disorders from the rarest to the most common.
Convelo Therapeutics – collaboration to discover and develop novel remyelinating medicines for patients with neurological disorders
Kineta Inc. – collaboration to explore novel non-opioid treatments for chronic pain
Tom Zioncheck, Head of Neuroscience, Ophthalmology and Rare Diseases, Pharma Partnering
J.C. Lopez, Search & Evaluation Lead Neuroscience, Ophthalmology & Rare Diseases, Pharma Partnering